Cargando…

Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling

BACKGROUND: Cardiac remodeling is one of the major risk factors for heart failure. In patients with type 2 diabetes, sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of the first hospitalization for heart failure, possibly through glucose-independent mechanisms in part, but the unde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuze, Lin, Xiaoyan, Chu, Yong, Chen, Xiaoming, Du, Heng, Zhang, Hailin, Xu, Changsheng, Xie, Hong, Ruan, Qinyun, Lin, Jinxiu, Liu, Jie, Zeng, Jinzhang, Ma, Ke, Chai, Dajun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196449/ https://www.ncbi.nlm.nih.gov/pubmed/34116674 http://dx.doi.org/10.1186/s12933-021-01312-8

Ejemplares similares

Activation of AHR by ITE improves cardiac remodelling and function in rats after myocardial infarction
por: Lin, Xiaoyan, et al.
Publicado: (2023)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

VDR Agonist Prevents Diabetic Endothelial Dysfunction through Inhibition of Prolyl Isomerase-1-Mediated Mitochondrial Oxidative Stress and Inflammation
por: Zhang, Meijin, et al.
Publicado: (2018)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)

Anti-fibrotic Effects of Synthetic Oligodeoxynucleotide for TGF-β1 and Smad in an Animal Model of Liver Cirrhosis
por: Kim, Jung-Yeon, et al.
Publicado: (2017)

Anti-Diabetic Atherosclerosis by Inhibiting High Glucose-Induced Vascular Smooth Muscle Cell Proliferation via Pin1/BRD4 Pathway
por: Wu, Yuansheng, et al.
Publicado: (2020)

TGF‐β/Smad and JAK/STAT pathways are involved in the anti‐fibrotic effects of propylene glycol alginate sodium sulphate on hepatic fibrosis
por: Xu, Shizan, et al.
Publicado: (2020)

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
por: Tahrani, Abd A., et al.
Publicado: (2011)

Design and Synthesis of Matrine Derivatives as Novel Anti-Pulmonary Fibrotic Agents via Repression of the TGFβ/Smad Pathway
por: Li, Lingyu, et al.
Publicado: (2019)

Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-β1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure
por: Chen, Xuefeng, et al.
Publicado: (2022)

All-Trans Retinoic Acid Attenuates Fibrotic Processes by Downregulating TGF-β1/Smad3 in Early Diabetic Nephropathy
por: Sierra-Mondragon, Edith, et al.
Publicado: (2019)

Amniotic fluid-derived exosomes attenuated fibrotic changes in POI rats through modulation of the TGF-β/Smads signaling pathway
por: Nazdikbin Yamchi, Nahideh, et al.
Publicado: (2023)

Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling
por: Cinato, Mathieu, et al.
Publicado: (2021)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
por: Choi, Jin Bong, et al.
Publicado: (2020)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
por: Choi, Min-Koo, et al.
Publicado: (2020)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Statins Inhibit Angiotensin II/Smad Pathway and Related Vascular Fibrosis, by a TGF-β-Independent Process
por: Rodrigues Díez, Raúl, et al.
Publicado: (2010)

PPARγ/NF‐κB and TGF‐β1/Smad pathway are involved in the anti‐fibrotic effects of levo‐tetrahydropalmatine on liver fibrosis
por: Yu, Qiang, et al.
Publicado: (2021)

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
por: Jariwala, Pankaj, et al.
Publicado: (2021)

MicroRNA-29a attenuates angiotensin-II induced-left ventricular remodeling by inhibiting collagen, TGF-β and SMAD2/3 expression
por: Zhang, Si-Jin, et al.
Publicado: (2020)

Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease
por: Wang, Qingjian, et al.
Publicado: (2011)

Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats
por: Tian, Jingjing, et al.
Publicado: (2021)

C3a Receptor Antagonist Ameliorates Inflammatory and Fibrotic Signals in Type 2 Diabetic Nephropathy by Suppressing the Activation of TGF-β/smad3 and IKBα Pathway
por: Li, Ling, et al.
Publicado: (2014)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors
por: Eickhoff, Mie K., et al.
Publicado: (2019)

Angiotensin II Facilitates Fibrogenic Effect of TGF-β1 through Enhancing the Down-Regulation of BAMBI Caused by LPS: A New Pro-Fibrotic Mechanism of Angiotensin II
por: Li, Yu-Sheng, et al.
Publicado: (2013)

Resveratrol inhibits TGF-β1–induced fibrotic effects in human pterygium fibroblasts
por: Fan, Jianwu, et al.
Publicado: (2023)

Pan-Phosphodiesterase Inhibitors Attenuate TGF-β-Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation
por: Wójcik-Pszczoła, Katarzyna, et al.
Publicado: (2022)

Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-β1/SMAD Signaling and Autophagy in Hepatic Stellate Cells
por: Kataoka, Seita, et al.
Publicado: (2021)

The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice
por: Wang, Dong, et al.
Publicado: (2018)

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
por: Cho, Kyu Yong, et al.
Publicado: (2020)

The Smad Dependent TGF-β and BMP Signaling Pathway in Bone Remodeling and Therapies
por: Zou, Ming-Li, et al.
Publicado: (2021)

Jia-Shen decoction-medicated serum inhibits angiotensin-II induced cardiac fibroblast proliferation via the TGF-β1/Smad signaling pathway
por: Cui, Lin, et al.
Publicado: (2016)

Regulation of the Cardiac Sodium/Bicarbonate Cotransporter by Angiotensin II: Potential Contribution to Structural, Ionic and Electrophysiological Myocardial Remodelling
por: Aiello, Ernesto Alejandro, et al.
Publicado: (2013)

Up-regulation of BMP-2 antagonizes TGF-β1/ROCK-enhanced cardiac fibrotic signalling through activation of Smurf1/Smad6 complex
por: Wang, Shijun, et al.
Publicado: (2012)

Suppression of ADAM8 attenuates angiotensin II-induced cardiac fibrosis and endothelial-mesenchymal transition via inhibiting TGF-β1/Smad2/Smad3 pathways
por: Yao, Lixia, et al.
Publicado: (2021)

TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
por: Pardali, Evangelia, et al.
Publicado: (2017)

TGF-β and TGF-β/Smad Signaling in the Interactions between Echinococcus multilocularis and Its Hosts
por: Wang, Junhua, et al.
Publicado: (2013)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nosvp9ar2qj90isq5ou080fa1a